Analyzing Enzalutamide Patient-Reported Outcomes and QOL in the EMBARK Trial With Stephen Freedland, MD

At this year’s American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland sat down to discuss two of his presentations which investigated patient-reported outcomes and quality of life (QOL) with enzalutamide for prostate cancer, including:

About Dr. Freedland

Stephen Freedland, MD, is Director of the Center for Integrated Research in Cancer and Lifestyle and Associate Director for Education and Training at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute in Los Angeles. As well, he is the Warschaw Robertson Law Families Chair in Prostate Cancer and a Professor in the Department of Urology at Cedars-Sinai. He holds a Staff Physician appointment at the Durham VA Medical Center in Durham, North Carolina. Dr. Freedland has published over 700 articles and served on numerous AUA and ASCO guideline panels for prostate cancer. His research interests include the role of diet, lifestyle, and obesity in cancer, cancer health disparities, and cancer risk stratification.

Related Articles


Your email address will not be published. Required fields are marked *